Immune checkpoint inhibitor (ICI) targeting PD-1 or PD-L1 have achieved huge clinical success in treating advanced non-small cell lung cancer (NSCLC) [1–6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.